Two-Center Experience in the Endovascular Treatment of Ruptured and Unruptured Intracranial Aneurysms Using the WEB Device: A Retrospective Analysis

J. Popielski, A. Berlis, W. Weber and S. Fischer

AJNR Am J Neuroradiol 2018, 39 (1) 111-117
doi: https://doi.org/10.3174/ajnr.A5413
http://www.ajnr.org/content/39/1/111

This information is current as of August 11, 2024.
Two-Center Experience in the Endovascular Treatment of Ruptured and Unruptured Intracranial Aneurysms Using the WEB Device: A Retrospective Analysis

J. Popielski, A. Berlis, W. Weber, and S. Fischer

ABSTRACT

BACKGROUND AND PURPOSE: The safety and efficacy of the Woven EndoBridge (WEB) device for the treatment of cerebral aneurysms has been investigated in several studies. Our objective was to report the experience of 2 neurovascular centers with the WEB device in the treatment of broad-based intracranial aneurysms, including the technical feasibility and safety as well as short- and midterm angiographic and clinical follow-up results.

MATERIALS AND METHODS: We performed a retrospective analysis of all ruptured and unruptured aneurysms treated with a WEB device (WEB Single-Layer and Single-Layer Sphere) between August 2014 and February 2017. Primary outcome measures included the feasibility of implantation and the angiographic outcome. Secondary outcome measures included the clinical outcome at discharge and procedural complications.

RESULTS: One hundred two aneurysms in 101 patients, including 37 (36.3%) ruptured aneurysms, were treated with the WEB device. Implantation was successful in 98 (96.1%) aneurysms. Additional devices (stents/coils) were necessary in 15.3% (15/98) of aneurysms. Procedural complications occurred in 4.9% (5/102). Of these, 4 were thromboembolic events and 1 was an intraprocedural rupture. Angiographic follow-up at 3 and 12 months was available for 79.6% (78/98) and 50.0% (49/98) of all aneurysms to date, respectively, showing a sufficient aneurysm occlusion in 80.7% (63/78) at 3 months and 77.6% (38/49) at 12 months. Delayed aneurysm ruptures have not been observed during the follow-up period to date.

CONCLUSIONS: The WEB device offers a safe and effective treatment option for broad-based intracranial aneurysms without the need for dual antiplatelet therapy.

ABBREVIATIONS: ASA = acetylsalicylic acid; WEB = Woven EndoBridge; DL = Dual-Layer; SL = Single-Layer; SLS = Single-Layer Sphere
(SL) and Single-Layer Sphere (SLS) devices in the endovascular treatment of ruptured and nonruptured intracranial aneurysms.

**MATERIALS AND METHODS**

**WEB Devices Used in This Series**
The WEB device is an intra-aneurysmal implant consisting of a self-expanding nitinol braid. The device is electrothermally detachable and is introduced through microcatheters with diameters dependent on the size of the device. The initial version was introduced as the WEB Dual-Layer (DL) in 2010, with a second mesh placed inside the primary braid to achieve increased coverage at the neck region of the aneurysm. This version was replaced by the WEB SL and WEB SLS in 2013, which are devices with a single-layer mesh, whereas the SLS version has a more spheric shape, designed for the treatment of rounded aneurysms compared with the barrel-like shape of the SL version. The available diameters of the recent versions range from 4 (144 wires) to 11 mm (216 wires) in 1-mm increments, with lengths ranging from 3 to 7 mm for the SL version. The length of the SLS device is determined by its diameter and results from a subtraction of 1.6 mm. Devices up to a diameter of 7 mm have been compatible with a 0.021-inch microcatheter since 2015, whereas diameters of 8 and 9 mm need an 0.027-inch microcatheter, and the largest sizes of 10–11 mm require a 0.033-inch microcatheter. The VIA Microcatheter (Sequent Medical) is designed for the delivery of the WEB device.

The aneurysms analyzed in the present study were exclusively treated with WEB SL and SLS versions.

**Inclusion and Exclusion Criteria**
Each case was discussed at an institutional neurovascular board, including neurosurgical, neurologic, and neurointerventional experts at the 2 participating neurointerventional centers. The decision for endovascular treatment was reached by consensus. The final endovascular treatment strategy was determined by the operator.

Criteria to use the WEB device were a wide neck and a fundus width between 3 and 10 mm. Arguments in favor of endovascular treatment compared with neurosurgical clipping were an aneurysm location in the posterior circulation and an anticipated surgical difficulty. Saccular aneurysms with a maximum width below 3 mm or above 10 mm (+1/-1 rule described below), those with a dome-to-neck ratio of <1 (missing stability for the WEB device), and fusiform and extradural aneurysms were not considered.

All patients were informed of the planned treatment usually before admission but at least 1 day before the procedure, except those with an acute SAH. The clinical status of each patient with an unruptured aneurysm was graded by the modified Rankin Scale on admission, at discharge, and at each follow-up visit by a neurovascular team member. Patients with an acute SAH were graded by the Hunt and Hess scale initially. All clinical and radiographic data were analyzed in retrospect. Complications that resulted in a permanent clinical decline were defined as relevant and were analyzed separately. The study was approved by the local ethics committee.

**Endovascular Procedure and Device Selection**
Procedures were performed with the patient under general anesthesia by 4 experienced interventionalists. In elective procedures, a dual antiplatelet medication with acetylsalicylic acid (ASA) and clopidogrel was initiated at least 1 day before the procedure (500 mg of ASA and 600 mg of clopidogrel followed by a daily dose of 100 mg of ASA and 75 mg of clopidogrel) to permit the possibility of stent-assisted coiling, if needed. The response to the antiplatelet medication was not routinely tested. Single antiplatelet therapy with 100 mg of ASA daily was continued for at least 1 month. All procedures were performed with an initial intravenous bolus of heparin (5000 IU).

An 8F/6F combination of guiding catheters or a 6F catheter alone was introduced into the target artery. The aneurysm was visualized in an angulation without superimposition of surrounding branches.

Size selection of the WEB resulted from exact calibrated measurements of the aneurysm (width and height of the fundus, width of the neck) in 2 orthogonal projections based on a 3D rotational angiographic dataset. Because a stable position of the WEB inside the aneurysm results from a slight oversizing of the device, 1 mm was added to the average width of the aneurysms to assure good wall apposition of the device inside the aneurysm. The height of the selected device was therefore 1 mm lower than the average height of the aneurysm to adjust for the longitudinal increase caused by the horizontal compression (+1/-1 rule).

An appropriate VIA microcatheter was placed inside the aneurysmal fundus followed by the deployment of the WEB, which results from a combination of forward pushing of the device with simultaneous withdrawal of the microcatheter.

At this point in the procedure, the appropriate position of the WEB device was documented under fluoroscopy or an additional angiographic run including 3D angiography. In procedures with residual contrast filling between the device and the aneurysmal wall (radial flow), the WEB was withdrawn and a larger device was implanted. A slight extension of the mesh and the proximal detachment marker into the parent artery was tolerated if no evidence of flow compromise or thrombus formation occurred during an observational period of at least 10 minutes. The device was removed or a self-expanding stent was implanted to protect the parent artery in cases of distinct malposition. The stable position of the WEB was documented on a final angiographic run after detachment under continuous fluoroscopy.

**Follow-Up Schedule**
Angiographic follow-up examinations were scheduled at 3 and 12 months after treatment. The angiographic results were evaluated independently by 2 neuroradiologists on the basis of a 5-grade scale as described by Caroff et al: 1, no residual flow in aneurysm/WEB; 2, opacification of the proximal recess of WEB; 3, neck remnant; 4, residual flow inside the WEB; 5, aneurysm remnant. Grades 1 and 2 were considered complete occlusion. Grades 1–3 indicated a sufficient aneurysm occlusion.

**Statistical Analysis**
The statistical analysis of all variables was performed independently with Excel (Microsoft, Redmond, Washington). Continuous variables were described by median and range. Independent variables were characterized as percentages.
**Ethical Standards and Patient Consent**

We declare that all human and animal studies have been approved by the ethics committee of Ruhr Universität Bochum, Germany, and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. A separate informed consent from each patient before inclusion in this study was not required due to the design of the study.

**RESULTS**

**Patient Population**

Between August 2014 and February 2017, one hundred one patients (median age, 58.6 years; range, 28–89 years) with 102 intracranial aneurysms were treated.

**Aneurysm Characteristics**

Of the 102 aneurysms treated in this series, 37 were acutely ruptured (maximum of 7 days from SAH to treatment), 60 were incidental findings, and 5 were remnants of previously coiled or clipped aneurysms. The median fundus width of all aneurysms was 6.0 mm (range, 4–10 mm) with a median neck width of 4.6 mm (range, 4–7 mm). Tables 1 and 2 summarize the locations and baseline characteristics.

**Procedural Results**

Implantation was successful in all except 4 aneurysms (3.9%), which were excluded from the follow-up analysis. In 2 cases of MCA aneurysms, the WEB was withdrawn due to a flow deceleration in the MCA branch originating from the aneurysm base. Another MCA aneurysm was not accessible with the microcatheter because of a severe elongation of the ICA, and 1 anterior communicating artery aneurysm was in a very tight angulation to the parent artery. The treatment strategy was changed to stent-assisted coiling in 3 procedures, and 1 aneurysm was finally clipped.

The procedure was completed with a WEB device only as intended in 83 (81.4%) aneurysms (Fig 1), whereas in 7 (6.9%), additional coils were necessary to completely fill the aneurysm. In another 8 (7.8%) procedures, a self-expanding stent was implanted to guarantee a stable position of the WEB. This was combined with additional coiling in 1 aneurysm.

**Immediate and Follow-Up Angiographic Results**

**In the Entire Series.** A first follow-up angiography was available for 78/98 (79.6%) aneurysms to date after a median of 3.5 months (range, 1.0–21.0 months), showing complete occlusion (grades 1 and 2) in 47/78 (60.2%) and sufficient aneurysm occlusion (grades 1–3) in 63/78 (80.7%). Of the remaining 20 patients, 9 died as consequence of their SAH, 9 were lost to follow-up, 1 died of causes unrelated to the treated aneurysm, and 1 died of causes related to the procedure (see below). A second follow-up angiography was performed in 49/98 (50.0%) after a median of 8.6 months (range, 2.0–21.0 months), showing complete occlusion in 29/49 (59.2%) and sufficient occlusion in 38/49 aneurysms (77.6%). Retreatment has been necessary in 10 aneurysms to date due to a regrowth of the aneurysms or a clustering of the WEB.

**In Unruptured Aneurysms.** At least 1 follow-up angiography was performed in 91.8% (56/61) of all unruptured aneurysms, showing complete occlusion in 60.8% (34/56) and sufficient occlusion in 82.2% (46/56). Thirty-seven of the 61 aneurysms (60.7%) were evaluated in a second angiography to date. Of those, 59.4% (22/37) were completely occluded and 78.3% (29/37) showed sufficient occlusion.

**In Ruptured Aneurysms.** Of the 37 aneurysms treated in the acute phase, 22 (59.5%) and 12 (32.4%) were examined at the first and second follow-ups. At the first follow-up, complete occlusion was 59.1% (13/22) compared with 58.3% (7/12) at the second follow-up. Accordingly, sufficient occlusion was 77.3% (17/22) and 75.0% (9/12).

Tables 3–5 summarize the immediate and follow-up angiographic results depending on the status of rupture.
resulting in morbidity and mortality rates of 4.0% (4/101 patients). Clinically relevant complications occurred in 5 patients (4.9%), indicating no residual flow in aneurysm/WEB; 2, opacification of the proximal recess of the WEB; 3, neck remnant; 4, residual flow inside the WEB; 5, aneurysm remnant.

Table 3: Immediate and follow-up results of ruptured aneurysms*

<table>
<thead>
<tr>
<th>Grade</th>
<th>Immediate</th>
<th>3-Month Follow-Up</th>
<th>12-Month Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>37 (100%)</td>
<td>22 (59.5%)</td>
<td>12 (32.4%)</td>
</tr>
<tr>
<td>1</td>
<td>5 (13.5%)</td>
<td>11 (50.0%)</td>
<td>6 (50.0%)</td>
</tr>
<tr>
<td>2</td>
<td>1 (2.7%)</td>
<td>2 (9.1%)</td>
<td>1 (8.3%)</td>
</tr>
<tr>
<td>3</td>
<td>2 (5.4%)</td>
<td>4 (18.2%)</td>
<td>2 (16.7%)</td>
</tr>
<tr>
<td>4</td>
<td>29 (78.4%)</td>
<td>2 (9.1%)</td>
<td>1 (8.3%)</td>
</tr>
<tr>
<td>5</td>
<td>0 (0.0%)</td>
<td>3 (13.6%)</td>
<td>2 (16.7%)</td>
</tr>
</tbody>
</table>

Table 4: Immediate and follow-up results of unruptured aneurysms*

<table>
<thead>
<tr>
<th>Grade</th>
<th>Immediate</th>
<th>3-Month Follow-Up</th>
<th>12-Month Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>61 (100%)</td>
<td>56 (91.8%)</td>
<td>37 (60.7%)</td>
</tr>
<tr>
<td>1</td>
<td>3 (4.9%)</td>
<td>22 (39.4%)</td>
<td>15 (40.5%)</td>
</tr>
<tr>
<td>2</td>
<td>5 (8.2%)</td>
<td>12 (21.4%)</td>
<td>7 (17.9%)</td>
</tr>
<tr>
<td>3</td>
<td>0 (0.0%)</td>
<td>12 (21.4%)</td>
<td>7 (17.9%)</td>
</tr>
<tr>
<td>4</td>
<td>53 (86.9%)</td>
<td>5 (8.9%)</td>
<td>3 (8.2%)</td>
</tr>
<tr>
<td>5</td>
<td>0 (0.0%)</td>
<td>5 (8.9%)</td>
<td>5 (13.5%)</td>
</tr>
</tbody>
</table>

Table 5: Immediate and follow-up results of ruptured and unruptured aneurysms*

<table>
<thead>
<tr>
<th>Grade</th>
<th>Immediate</th>
<th>3-Month Follow-Up</th>
<th>12-Month Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>98 (100%)</td>
<td>78 (79.6%)</td>
<td>49 (50.0%)</td>
</tr>
<tr>
<td>1</td>
<td>8 (8.2%)</td>
<td>33 (42.3%)</td>
<td>21 (42.9%)</td>
</tr>
<tr>
<td>2</td>
<td>6 (6.1%)</td>
<td>14 (17.9%)</td>
<td>8 (16.3%)</td>
</tr>
<tr>
<td>3</td>
<td>2 (2.0%)</td>
<td>16 (20.5%)</td>
<td>9 (18.4%)</td>
</tr>
<tr>
<td>4</td>
<td>82 (83.7%)</td>
<td>7 (9.0%)</td>
<td>4 (8.1%)</td>
</tr>
<tr>
<td>5</td>
<td>0 (0.0%)</td>
<td>8 (9.3%)</td>
<td>7 (14.3%)</td>
</tr>
</tbody>
</table>

Peri- and Early Postprocedural Clinically Relevant Complications

Clinically relevant complications occurred in 5 patients (4.9%), resulting in morbidity and mortality rates of 4.0% (4/101 patients) and 1.0% (1/101 patients), respectively.

Of those, 4 were thromboembolic compared with 1 intraprocedural rupture. One patient with an incidental middle cerebral artery aneurysm (M1 segment) and the temporal branch arising close to the aneurysm neck was treated with a WEB SL (6 × 3) device. The proximal part of the device slightly extended into the parent artery without evidence of thrombus formation. Nevertheless, the operator decided to place a self-expanding stent (LVIS; MicroVention, Tustin, California) to stabilize the device. The procedure was finished without flow compromise in the parent artery or the temporal branch. Approximately 30 minutes later, the patient developed a hemiparesis of the left arm. Angiography revealed a thrombotic occlusion of the temporal branch with no flow compromise in the M1 segment. The aneurysm showed complete occlusion. After an interdisciplinary discussion, 20 mL of alteplase (Actilyse; Boehringer Ingelheim Pharma, Germany) was infused for 30 minutes with a microcatheter placed in the proximal M1 segment, which resulted in a complete recanalization of the branch. The decision to use alteplase was derived by consensus, even though a recently published meta-analysis showed lower morbidity rates with glycoprotein IIb/IIa inhibitors. The paresis of the left arm remained unchanged (mRS 3). MR imaging performed 2 days later revealed an ischemic lesion in the right MCA territory.

Another 89-year-old patient with a ruptured ICA posterior communicating artery aneurysm was treated with a WEB SL (5 × 3) without extension into the ICA; 30 minutes after the procedure, the patient showed a left-sided hemiplegia. Angiography revealed a thrombotic occlusion of the terminal ICA, treated by an intra-arterial infusion of 33 mL of tirofiban without complete resolution of the thrombus after an observational period of 120 minutes. A mechanical thrombectomy with a pRSet system (phenox, Bochum, Germany) resulted in complete recanalization. Another 20 minutes later, angiography showed a recurrent thrombus formation at the aneurysm orifice, which was successfully treated with a self-expanding stent (Neuroform Atlas; Stryker Neurovascular, Kalamazoo, Michigan). The patient was placed on ticagrelor thereafter. The procedure was terminated without evidence of further thrombus formation or an intracranial hemorrhage. The hemiplegia remained. One day later the patient declined finally to a coma status. CT revealed a complete infarction of the right MCA and anterior cerebral artery territory with massive swelling. A day later, the patient died.

The remaining thromboembolic complications both occurred in incidental aneurysms (MCA and anterior cerebral artery) treated with additional self-expanding stents (LVIS). Both patients showed clinically relevant strokes on postprocedural CT scans without evidence of in-stent thrombosis, probably related to distal emboli caused by the stent implantation resulting in an mRS grade of 3.

In 1 case of a ruptured ICA aneurysm, a rerupture occurred with a VIA 27 microcatheter. The microcatheter was left in place followed by the implantation of a WEB (SL 8 × 6) partially outside the aneurysm, which resulted in prompt hemostasis. The remaining aneurysm was then occluded by stent-assisted coiling (Neuroform Atlas). A left-sided hemiparesis resolved completely (Fig 2A–D).

Delayed Complications

Neither delayed aneurysm ruptures nor thromboembolic complications have been observed during the follow-up period to date.
versus 5.6%). Adeeb et al,23 in their series of 74 aneurysms treated
while the rate of complications was significantly higher (9.4%
found a lower rate of recurrence in the group treated with stents,
events was significantly higher in the group of 16 patients with-
the WEB DL (n = 26). The rate of ruptured aneurysms in this series was 7.3%
complete occlusion rate of 54.0% and a neck remnant in
Low-Intracranial Aneurysms (WEB-LIA) trial, determined a technical success rate of 96.1% and the rate of thrombo-
embolic complications (3.9%) are comparable with those re-
ported in the literature.14-21
The main drawback of stent-assisted coiling is the need for
dual antiplatelet medication. Nishido et al22 compared the clinical
and angiographic results of 1815 saccular aneurysms treated with
stents (n = 299) with those treated without (n = 1492). They
found a lower rate of recurrence in the group treated with stents,
while the rate of complications was significantly higher (9.4%
versus 5.6%). Adeeb et al,23 in their series of 74 aneurysms treated
with a single stent, observed an immediate complete occlusion
rate of 52.7% with an improvement to 70.3% during the fol-
low-up period of 15.2 months. These results are comparable with
those in our series.
Our results are in line with those of previously published
series: Pierot et al17 presented the results of 55 aneurysms
treated at 10 neurointerventional centers. They found a 1-year
complete occlusion rate of 54.0% and a neck remnant in
26.0%. The rate of ruptured aneurysms in this series was 7.3%
(n = 4). The mortality rate at 1 year was 2.0%. The results of 2
good clinical practice studies with the WEB device (WEBCAST
and French Observatory) are analyzed in another publication of
Pierot et al.24 In the cumulated series of 114 aneurysms
treated with the WEB DL (n = 82) and the WEB SL/SLS (n = 32), 10 aneurysms were ruptured. The rate of thromboembolic
events was significantly higher in the group of 16 patients with-
out a prophylactic antiplatelet medication (56.3%) compared
with those with 1 antiplatelet agent 12% (6/50). These data
might diminish the advantage of the WEB device against stent-
assisted coiling and indicate the need for at least 1 antiplatelet
agent in elective procedures, but 71.9% of all aneurysms in this
series were treated with the WEB DL version, which might be
of a higher thrombogenicity, probability due to the double-
layer surface at the aneurysm orifice.
A dual antiplatelet therapy was initiated in all elective patients
of our series. The medication with ASA, 100 mg, was continued
for at least 4 weeks as described above. In patients with an acute
SAH, the procedure was performed without a periprocedural an-
tiplatelet medication followed by a monotherapy with 100 mg of
ASA for at least 4 weeks.
Fiorella et al18 presented the 30-day safety results of the WEB
Intrasaccular Therapy (WEB-IT) study. They recommended a
monotherapy with 100 mg of ASA before the procedure in less
complex cases, while in broad-based anatomies, they initiated a
dual antiplatelet therapy continued for 90 days if a protrusion of
the WEB into the parent artery occurred. They observed 7 minor
ischemic strokes during the follow-up period, with 2 of them re-
sulting in an mRS of 1. Adjunctive devices were used in 7 aneu-
rysms (2 stents, 7 balloons). Treatment with the WEB device
failed in 2 patients. The mortality rate in the entire series is 0% to
date.

**DISCUSSION**
In this retrospective study, we analyzed the angiographic and clini-
cal results in the treatment of both ruptured and unruptured
intracranial aneurysms with the WEB device.

The technical success rate of 96.1% and the rate of thrombo-
embolic complications (3.9%) are comparable with those re-
ported in the literature.14-21

**Technical Aspects**
As described above, we encountered 1 intra procedural rupture.
Van Rooij et al21 in their series of 32 acutely ruptured aneurysms
treated with the WEB device observed no procedural perforation.
However, acutely ruptured aneurysms are generally known for
their higher risk of procedural perforations.16,25 Deployment of
the WEB should be performed without contact of the device to the
aneurysm wall until two-thirds of the mesh is unfolded. At this
point, the device engages a centered position inside the aneurysm
with invagination of its tip. The possibility of implanting a WEB
device with a 0.017-inch microcatheter (not used in our study)
might ease the procedure.

**Thromboembolic Complications**
The rate of thromboembolic complications in our cohort is simi-
lar to that in other studies. Pierot et al17 observed thromboemb-
olic events in 9 of 51 (17.7%) patients. They found a trend to-
ward lower thromboembolic complications with the WEB SL/SLS
compared with the WEB DL version, which was not used in our
series. Most interesting, 3 of the thromboembolic complications
in our series occurred with self-expanding stents. This might in-
dicate the positive relation between adjunctive devices and
thromboembolic complications.

The importance of a meticulous case and device selection be-
comes clear against these findings because the need for additional
devices will be lower with an exact fitting between the aneurysm
and the WEB device.

Lawson et al15 in their series of 22 aneurysms treated with the
WEB device observed 1 symptomatic ischemic event. The WEB
used in this case was oversized. These findings are similar to those
of Caroff et al,20 who found 2 strokes in their series due to the use
of oversized WEB devices. The authors concluded that undersizing can lead to recurrence and residual aneurysm, while excessive oversizing may promote clot formation and thromboembolism.

**Follow-Up Results**

While standard coiling procedures result in an absence of contrast media, aneurysms treated with the WEB frequently show a remaining perfusion after implantation. This impedes a direct comparison between the techniques and raises the question of sufficient protection from further ruptures. We did not observe any cases of aneurysm rupture during the follow-up period either in the incidental or ruptured group.

We classified the angiographic results on the basis of a 5-point scale as suggested by Caroff et al. This, in contrast to a 3-point scale, allows differentiation between a typical aneurysm remnant, which might require retreatment in the future, and an opacification inside the mesh of the WEB, which might result in a contemporaneous intra-aneurysmal thrombosis without additional treatment. Mine et al, in their recently published series of 49 aneurysms treated with the WEB device, demonstrated that a small proximal recess related to the device should not be considered a remnant and remains stable with time. According to these findings, the rate of complete aneurysm occlusion at 3 and 12 months is 60.2% (47/78) and 59.2% (29/49), respectively, in our series.

Our results with a sufficient occlusion of almost 80% are comparable with those in previously published series. We have observed no major difference between ruptured and unruptured aneurysms during the follow-up period to date, though the comparability of the 2 groups is restricted due to the different sample sizes.

**Advantages and Disadvantages in Ruptured Aneurysms**

The main advantage is the possibility of treating ruptured aneurysms without periprocedural antiplatelet medication. Another major benefit consists of the reduced overall procedure time. An analysis of the WEB-IT study showed that one-third of all procedures were completed in <20 minutes. This is in line with our experience, though we did not analyze the procedure times. We observed 1 intraprocedural rupture that was rapidly stopped by the implantation of the WEB, similar to the findings in the WEB-IT cohort with 2 hemorrhages. The capability of the WEB to induce hemostasis promptly is another advantage. The limitation in size and the learning curve with this new device might be considered a temporary drawback compared with standard concepts.

**Limitations of the Study**

Our study has several limitations. The retrospective character of the study with 2 different centers might cause inhomogeneity of the data. Factors such as the number of attempts before implantation of the device, duration of the procedure, and the learning curve were not considered. The limited number of treated aneurysms and follow-up data impedes a separate analysis of ruptured and unruptured aneurysms. The angiographic results were classified without an independent assessment.

**CONCLUSIONS**

The WEB device offers a safe and effective treatment option for broad-based aneurysms, independent of the status of rupture, without the need for a dual antiplatelet therapy. Proper device selection appears to be a key factor in minimizing the risk of thromboembolic complications and may increase the rate of sufficient aneurysm occlusion. Further studies with longer follow-up data will prove the significance of the presented therapy.

Disclosures: Amrge Berlis—RELATED: Consulting Fee or Honorarium: Sequent Medical, MicroVention; Comments: proctor contract; UNRELATED: Consultancy: Stryker, Medtronic; Comments: proctor contract; Payment for Lectures Including Service on Speakers Bureaus: Penumbra. Werner Weber—RELATED: Consultancy: R&D team of Sequent, MicroVention; Payment for Lectures Including Service on Speakers Bureaus: MicroVention; Other: proctoring the WEB device in Europe and Germany.* Sebastian Fischer—UNRELATED: Board Membership: Codman Neurovascular; Comments: Advisory Board, Payment for Lectures Including Service on Speakers Bureaus: Sequent Medical, Comments: speaking honorarium. *Money paid to the institution.

**REFERENCES**


